We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA SETS DEADLINE FOR NDAs ON ALL PANCREATIC EXTRACT PRODUCTS
FDA SETS DEADLINE FOR NDAs ON ALL PANCREATIC EXTRACT PRODUCTS
April 27, 2004
Manufacturers of all exocrine pancreatic insufficiency drug products (PIDs) will have to submit new drug applications (NDAs) to the FDA and have them approved within the next four years to remain on the market.